DiaSorin Launches the two Fastest Molecular Diagnostic Tests in the World to Detect Fulminant Leukemias

DiaSorin has launched 2 new molecular diagnostic tests, Iam PML-RARA Detection bcr1,3 and Iam PML-RARA Discrimination bcr2, available on the market outside the US, for the identification of the genetic cause of Acute Promyelocytic Laukemia.

When used together, the new tests allow reliable, complete and extremely fast (15 minutes instead of 4 hours) detection of the PML-RARA translocation, which is the genetic cause of “Fulminant Leukemia”, technically called Acute Promyelocytic Laukemia, which is considered the most aggressive type of blood cancer that, if not identified in time, is fatal.

The timing of DiaSorin tests will allow medical staff to treat the patient immediately with effective therapies, ensuring the patient’s care and surviving in more than 90% of cases.

Paul Eros, Global Vice President of Marketing Molecular in DiaSorin, commented: “After the launch, at the end of 2014, of the first test for the diagnosis of chronic myeloid leukemia and Ph + acute lymphoblastic leukemia, DiaSorin today marks another important milestone within onco-haematology. The two new tests based on our innovative proprietary Q-LAMP technology are the only solution available on the market for ultra-rapid molecular diagnosis of Acute Promyelocytic Leukemia. In just 15 minutes, from today, you can save an extra life”.

Carlo Rosa, CEO of DiaSorin Group, commented: “I am proud of our new successful launch in the field of onco-haematology that demonstrates once again our commitment to innovative molecular diagnostics research. Acute Promyelocytic Leukemia represents the urgency "par excellence" where time to results can make the difference between life and death and where DiaSorin offers the fastest solution on the market”.